Hallux Valgus - Pipeline Insight, 2019

"Hallux Valgus - Pipeline Insight, 2019" report by outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hallux Valgus pipeline landscape is provided which includes the disease overview and Hallux Valgus treatment guidelines. The assessment part of the report embraces, in depth Hallux Valgus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hallux Valgus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Hallux Valgus Understanding
According to National Institute of Health (NIH), a bunion, known technically as Hallux Valgus, is a bony bump on the side of the foot at the base of the big toe. Bunions develop slowly as pressure on the joint at the base of the big toe causes the toe to move out of place, leaning inward toward the second toe. It is a progressive foot deformity in which the first metatarsophalangeal (MTP) joint is affected and is often accompanied by significant functional disability and foot pain. At a late stage, these changes lead to pain and functional deficit: i.e. impaired gait (lateral and posterior weight shift, late heel rise, decreased single-limb balance, and pronation deformity). Bunions may be hereditary, as they often run in families. This suggests that people may inherit a faulty foot shape. In addition, footwear that does not fit properly may cause bunions. Bunions are made worse by shoes that are tight, fit poorly, or are too small. Bunions may also be caused by inflammatory conditions such as arthritis. Many people do not experience symptoms in the early stages of bunion formation. Symptoms are often most noticeable when the bunion gets worse and with certain types of footwear. These include shoes that crowd the toes and/or high-heeled shoes. When symptoms do occur, they may include: physical discomfort or pain, a burning feeling, redness, swelling, possible numbness and difficulty in walking.
Hallux Valgus Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Hallux Valgus targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Hallux Valgus pipeline report covers 8+ companies. Some of the key players include Ipsen (Botulinum toxin A) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Hallux Valgus Analytical Perspective by Report
• In-depth Hallux Valgus Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
• Hallux Valgus Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
• The Hallux Valgus report provides an overview of therapeutic pipeline activity for Hallux Valgus across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Hallux Valgus therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Hallux Valgus Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Hallux Valgus
Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Hallux Valgus to formulate effective R&D strategies
• Assess challenges and opportunities that influence Hallux Valgus R&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Hallux Valgus in licensing and out licensing strategies by identifying prospective partners with progressing projects for Hallux Valgus to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs